The Zepbound label (effective August 28, 2026) covers weight management in adults with obesity or overweight with a related condition, and moderate to severe obstructive sleep apnea in adults with obesity. In SURMOUNT-1 (NEJM 2022), the 15 mg dose produced 20.9% average weight loss at 72 weeks (treatment-regimen estimand). Lilly’s self-pay vials start at $299 a month, a figure Lilly repeated on November 6, 2026; its full dose ladder was not re-read because lilly.com returned HTTP 403. The Medicare.gov GLP-1 Bridge page says the Bridge covers the Zepbound KwikPen only, not vials.